Synergistic tumor inhibition of colon cancer cells by nitazoxanide and obeticholic acid, a farnesoid X receptor ligand

Junhui Yu,Kui Yang,Jianbao Zheng,Wei Zhao,Xuejun Sun

DOI: https://doi.org/10.1038/s41417-020-00239-8

IF: 5.854

2020-10-13

Cancer Gene Therapy

Abstract:Abstract The tumor-suppressive role of Farnesoid X receptor (FXR) in colorectal tumorigenesis supports restoring FXR expression as a novel therapeutic strategy. However, the complicated signaling network and tumor heterogeneity hinder the effectiveness of FXR agonists in the clinical setting. These difficulties highlight the importance of identifying drug combinations with potency and specificity to enhance the antitumor effects of FXR agonists. In this study, we found that the β-catenin level affected the antitumor effects of the FXR agonist OCA on colon cancer cells. Mechanistic studies identified a novel FXR/β-catenin complex in colon cancer cells. Furthermore, the depletion of β-catenin expedited FXR nuclear localization and enhanced its occupancy of the SHP promoter and thereby sensitized colon cancer cells to OCA. Furthermore, we utilized a drug combination study and identified that the antiparasitic drug nitazoxanide (NTZ) abrogated β-catenin expression and acted synergistically with OCA in colon cancer cells. The combination of OCA plus NTZ exerts synergistic tumor inhibition in CRC both in vitro and in vivo by cooperatively upregulating SHP expression. In conclusion, our study offers useful evidence for the clinical use of FXR agonists combined with β-catenin inhibitors in combating CRC.

oncology,genetics & heredity,medicine, research & experimental,biotechnology & applied microbiology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is: how to enhance the anti - tumor effect of FXR agonists in the treatment of colorectal cancer (CRC) through drug combinations. Specifically, the researchers found that the level of β - catenin affects the anti - tumor effect of the FXR agonist OCA on colorectal cancer cells, and explored the possibility of improving the efficacy of OCA by reducing β - catenin expression. They tested the effect of the combination of the antiparasitic drug nitazoxanide (NTZ) and OCA, and found that this combination can synergistically inhibit the growth of colorectal cancer cells, showing a significant synergistic anti - tumor effect both in vitro and in vivo experiments.

The main contributions of the paper are:
1. Revealing the influence of the level of β - catenin on the anti - tumor effect of the FXR agonist OCA.
2. Verifying that NTZ can enhance the anti - tumor effect of OCA by reducing β - catenin expression.
3. Providing in - vivo and in - vitro experimental data on the combined use of NTZ and OCA, proving the effectiveness and potential clinical application value of this combination therapy.